Form 8-K - Current report:
SEC Accession No. 0001104659-22-114895
Filing Date
2022-11-04
Accepted
2022-11-04 16:06:05
Documents
13
Period of Report
2022-10-31
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2229531-1_8k.htm   iXBRL 8-K 31412
  Complete submission text file 0001104659-22-114895.txt   252443

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fbio-20221031.xsd EX-101.SCH 3618
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fbio-20221031_def.xml EX-101.DEF 27289
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbio-20221031_lab.xml EX-101.LAB 37014
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbio-20221031_pre.xml EX-101.PRE 25911
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2229531-1_8k_htm.xml XML 5455
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 221362358
SIC: 2834 Pharmaceutical Preparations